BAR1 LIFE Share Price Australian S.E.

Equities

BD1

Biotechnology & Medical Research

End-of-day quote Australian S.E. 5-day change 1st Jan Change
- AUD -.--% Intraday chart for BAR1 LIFE -.--% -.--%

Financials

Sales 2024 * 1.6M 1.05M 87.26M Sales 2025 * 6.4M 4.18M 349M Capitalization 46.93M 30.69M 2.56B
Net income 2024 * -8M -5.23M -436M Net income 2025 * -5M -3.27M -273M EV / Sales 2024 * 24.9 x
Net cash position 2024 * 7.1M 4.64M 387M Net cash position 2025 * 9.4M 6.15M 513M EV / Sales 2025 * 5.86 x
P/E ratio 2024 *
-5.48 x
P/E ratio 2025 *
-11.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 71.68%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 07/16/07
Director of Finance/CFO - 02/22/02
Chief Tech/Sci/R&D Officer - 20/21/20
Members of the board TitleAgeSince
Chairman 70 29/11
Director/Board Member 65 18/19/18
Director/Board Member - 28/20/28
More insiders
INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and commercializing exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It operates in one segment, the research and development of cancer diagnostics. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.
More about the company

Annual profits - Rate of surprise